ArticleReports of biochemistry & molecular biology2018
An
Article in Reports of biochemistry & molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Comprehensive scientific insights on plant inspired nano therapeutics as the missing piece of the breast cancer puzzle.Discover nano · 2026Review
- Update on the Association of CD44 Expression with Esophageal Squamous Cell Carcinoma Invasion.Reports of biochemistry & molecular biology · 2025Article
- Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy.Pharmaceutics · 2025Review
- Nanocurcumin in cancer treatment: a comprehensive systematic review.Discover oncology · 2024Review
- Network pharmacology and molecular docking reveal the mechanisms of curcumin activity against esophageal squamous cell carcinoma.Frontiers in pharmacology · 2024Article
- Nanodrugs systems for therapy and diagnosis of esophageal cancer.Frontiers in bioengineering and biotechnology · 2023Review
- The theranostic potentialities of bioavailable nanocurcumin in oral cancer management.BMC complementary medicine and therapies · 2022Article
- Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression.The Kaohsiung journal of medical sciences · 2022Article
- The Benefits of Curcuminoid to Expression Nuclear Factor Erythroid 2 Related Factor 2 (NRF2) and Signal to Noise Ratio (SNR) Value in the Noise Exposed Organ of Corti of Rattus Norvegicus.Reports of biochemistry & molecular biology · 2021Article
- Curcumin Nanoparticles as Promising Therapeutic Agents for Drug Targets.Molecules (Basel, Switzerland) · 2021Review
- Updated Review on the Role of Curcumin in Gastrointestinal Cancers.Advances in experimental medicine and biology · 2021Review
- Gender associated effects of the ethanolic extracts of Chinese propolis on the hepatic transcriptome in ethanol-treated mice.Iranian journal of basic medical sciences · 2019Article
- The effect of nanomicelle curcumin, sorafenib, and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7).Iranian journal of basic medical sciences · 2019Article
- Effects of Curcumin on Microglial Cells.Neurotoxicity research · 2019Review
- Curcumin-Loaded Mesoporous Silica Nanoparticles Markedly Enhanced Cytotoxicity in Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2019Article
- Nano-curcumin's suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression.Breast cancer (Dove Medical Press) · 2019Article
- Bioactivity, Health Benefits, and Related Molecular Mechanisms of Curcumin: Current Progress, Challenges, and Perspectives.Nutrients · 2018Review
- Effect of nano-micelle curcumin on hepatic enzymes: A new treatment approach for non-alcoholic fatty liver disease (NAFLD).Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of esophageal squamous cell carcinoma (ESCC) is increasing, causing catastrophic health burdens on communities. Curcumin has shown promise as a therapeutic agent in the treatment of colon, colorectal, pancreatic, and esophageal cancers but it has very poor bioavailability. The application of nano-carriers as drug delivery systems increases curcumin's bioavailability. Cyclin D1 is overexpressed in ESCC and curcumin may change its expression.
methodsIn this study, the effect of SinaCurcumin®, a novel nano-micelle product containing 80 mg curcumin, on the growth of KYSE-30 cells and expression of cyclin D1, was investigated. Paclitaxel and Carboplatin served as reference drugs.
resultsNano-curcumin increased cell cytotoxicity, decreased IC
conclusionNano-curcumin suppressed proliferation of KYSE-30 cells and expression of cyclin D1 although its use in combination with other chemotherapeutic agents requires further testing.
Indexed as
Identifiers
29765996PMC5941128W2767878160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.